These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 23146479

  • 21. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y.
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [Abstract] [Full Text] [Related]

  • 22. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F.
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [Abstract] [Full Text] [Related]

  • 23. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M, Coelho EB.
    Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
    [Abstract] [Full Text] [Related]

  • 24. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [Abstract] [Full Text] [Related]

  • 25. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E, Şahin G, Kaltuş Z, Çolak E.
    Clin Lab; 2019 Nov 01; 65(11):. PubMed ID: 31710427
    [Abstract] [Full Text] [Related]

  • 26. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R.
    Exp Clin Transplant; 2015 Apr 01; 13 Suppl 1():197-200. PubMed ID: 25894154
    [Abstract] [Full Text] [Related]

  • 27. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
    Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN.
    J Heart Lung Transplant; 2011 Dec 01; 30(12):1352-9. PubMed ID: 21930396
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N.
    Transplant Proc; 2010 Nov 01; 42(9):3455-8. PubMed ID: 21094796
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F, He XJ, Sun YX, Li-Ling J, Zhao LM.
    Pharmacol Rep; 2011 Nov 01; 63(3):815-25. PubMed ID: 21857093
    [Abstract] [Full Text] [Related]

  • 33. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
    Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Biondi F, Sanguedolce R, Vizzini G, Palazzo U, Polidori P, Triolo F, Gridelli B, D'Alessandro N.
    Ann Transplant; 2009 Nov 01; 14(1):23-31. PubMed ID: 19289993
    [Abstract] [Full Text] [Related]

  • 34. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.
    Yoon JG, Song SH, Choi S, Oh J, Jang IJ, Kim YJ, Moon S, Kim BJ, Cho Y, Kim HK, Min S, Ha J, Shin HS, Yang CW, Yoon HE, Yang J, Lee MG, Park JB, Kim MS, and the Korean Organ Transplantation Registry (KOTRY) study group.
    Transplantation; 2021 Oct 01; 105(10):2213-2225. PubMed ID: 33654003
    [Abstract] [Full Text] [Related]

  • 35. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.
    Tavira B, Coto E, Diaz-Corte C, Alvarez V, López-Larrea C, Ortega F.
    Pharmacogenet Genomics; 2013 Aug 01; 23(8):445-8. PubMed ID: 23778326
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.
    Shi D, Xie T, Deng J, Niu P, Wu W.
    Eur J Clin Pharmacol; 2018 Jun 01; 74(6):723-729. PubMed ID: 29546446
    [Abstract] [Full Text] [Related]

  • 38. Unusual high dose of tacrolimus in liver transplant patient, a case report.
    Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, D'Antoni A, Polidori P, Vizzini G, D'Alessandro N.
    Int J Clin Pharm; 2012 Apr 01; 34(2):269-71. PubMed ID: 22422348
    [Abstract] [Full Text] [Related]

  • 39. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N, Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-Vernet S, van Schaik R, Grinyó JM.
    Pharmacogenet Genomics; 2017 Sep 01; 27(9):313-322. PubMed ID: 28704257
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.